Canaccord analyst William Plovanic lowered the firm’s price target on AtriCure (ATRC) to $51 from $52 and keeps a Buy rating on the shares. The firm said posted a solid Q1, with revenue relatively in line with estimates and the company continuing to show better than expected adjusted EBITDA. and they continue to believe that AtriCure is a compelling name, especially given the muted tariff exposure and impacts.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- Atricure’s Strong Q1 2025 Performance and Conservative Guidance Justifies Buy Rating Despite Price Target Adjustment
- AtriCure, Inc. Reports Strong Q1 2025 Growth
- AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M
- AtriCure reports Q1 adjusted EPS (14c), consensus (22c)
- ATRC Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue